JP Morgan Maintains Overweight on HilleVax, Raises Price Target to $24
Portfolio Pulse from Benzinga Newsdesk
JP Morgan analyst Eric Joseph maintains an Overweight rating on HilleVax (NASDAQ:HLVX) and raises the price target from $21 to $24.
May 15, 2024 | 5:22 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
JP Morgan analyst Eric Joseph has maintained an Overweight rating on HilleVax and increased the price target from $21 to $24, indicating a positive outlook for the stock.
The increase in the price target from $21 to $24 by a reputable analyst at JP Morgan suggests a positive outlook for HilleVax. This is likely to boost investor confidence and could lead to a short-term increase in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100